RxDoctor Payments Data

James Bonds, MD

Internal Medicine · Bryan, TXNPI 1093709511

Payments from drug & device makers

$3,561in general payments, 2019–2025

Across 151 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$649
  • Pfizer$250
  • Amgen$216
  • Lilly USA, LLC$163
  • AbbVie$159
  • plus $663 from 13 others

What the payments were for

  • Food & beverage$3,561100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,561 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$123,598
Medicare patients
274
Services billed
2,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide138$166,064
EliquisApixaban47$62,317
BiktarvyBictegrav/Emtricit/Tenofov Ala13$48,884
XareltoRivaroxaban11$15,788
JanuviaSitagliptin Phosphate17$15,226
FarxigaDapagliflozin Propanediol14$13,966
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$10,105
Bydureon BciseExenatide Microspheres12$9,662
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$5,171
Levothyroxine Sodium257$5,076
Rosuvastatin Calcium272$4,453
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$4,013
SynthroidLevothyroxine Sodium67$3,355
Temazepam17$2,127
Losartan Potassium127$2,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$649$166,064138 claims
PfizerEliquis$250$62,31747 claims
Johnson & JohnsonXarelto$13$15,78811 claims
MerckJanuvia$13$15,22617 claims
AstraZenecaFarxiga$1,462$13,96614 claims
AbbVieSynthroid$159$3,35567 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Bryan

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →